Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Rodin Therapeutics Applies Insights of Epigenetics to Neurological Disorders

Published: Monday, July 01, 2013
Last Updated: Monday, July 01, 2013
Bookmark and Share
Founded by Atlas Venture and Proteros biostructures.

Rodin Therapeutics has announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros’ best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience.

Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).

“The field of cognitive disorders such as Alzheimer’s Disease represents a critical unmet medical need with a large opportunity for new therapeutics,” said Dr. Bruce Booth, Acting CEO of Rodin Therapeutics.

Dr. Booth continued, “We are excited to launch Rodin Therapeutics as a capital efficient vehicle to take a novel, epigenetics guided approach to these diseases.”

The Rodin platform and pipeline is the product of a strategic partnership with Proteros, a leader in structural biology, biophysical profiling and integrated lead discovery.

Proteros’ capabilities enable an orthogonal look at the interactions of small molecules as they bind to key epigenetic targets.

Proteros is a founding shareholder in Rodin, and will offer Rodin privileged access to leading-edge technology and exclusive rights to key targets.

The Rodin team and Proteros scientists will work together to advance the Rodin pipeline and discovery efforts.

Dr. Torsten Neuefeind, CEO of Proteros commented: “We are excited about the founding of Rodin Therapeutics and to join the high caliber team of CNS experts and blue chip investors. This is a further validation of our structure-based discovery platform for a novel neuroscience approach.

Arnd Christ, CFO of Proteros added: “Rodin represents an innovative target focused financing approach to address the interest of all parties involved.”

The Johnson & Johnson Innovation Center in Boston and Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, will engage in scientific collaboration with Rodin Therapeutics with the goal of sharing knowledge and expertise to advance novel solutions in CNS.

A member of the Boston Innovation Center will participate on the company’s Scientific Advisory Board.

Rodin has assembled a team with deep drug discovery and company creation experience including Martin Jefson PhD, former head of Neuroscience Research at Pfizer (Chief Scientific Officer); Ankit Mahadevia MD, Venture Partner at Atlas Venture (Acting Chief Business Officer); Bruce Booth, PhD, Partner at Atlas Venture (Acting Chief Executive Officer).

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteros, Merck Sharp & Dohme Corp. Collaborate
Proteros to receive upfront and research funding plus milestone payments of up to $126 million plus royalties.
Wednesday, October 07, 2015
Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer
Dr. Hoffmann will support the further growth of the Company’s Discovery business.
Tuesday, June 30, 2015
Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
Company to discover potent and selective small molecule inhibitor series against a novel protein target.
Tuesday, May 19, 2015
Proteros Enters into a Collaboration with Bayer
Collaboration to develop new cardiovascular drug compounds for an integral membrane protein.
Saturday, January 10, 2015
Proteros Announces Changes in Management Team
The changes see a new Chief Financial Officer, and a promotion to Chief Operating Officer.
Monday, May 12, 2014
Proteros Elects New Supervisory Board Member
Shareholders confirmed the appointment of Prof. Eric-Paul Pâques as a new member of the Supervisory Board.
Thursday, February 20, 2014
Proteros and Eisai Announces Successful Completion of Collaboration
Proteros and Eisai achieve target in lead discovery project, delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
Proteros and Eisai Achieve Target in Lead Discovery Project
Companies delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets
Proteros biostructures GmbH announced they entered into a Lead Discovery Collaboration with Priaxon AG to jointly develop lead compounds for high value protein-protein interaction (PPI) drug targets.
Tuesday, April 09, 2013
UCB and Proteros Expand Collaboration
Expansion of the ongoing structural biology collaboration will include additional therapeutic areas.
Monday, September 17, 2012
Proteros Announces Successful Close of Financing Round
Largest-ever financing allows for expansion of drug discovery capabilities.
Tuesday, August 07, 2012
Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
Companies partner to identify small molecule inhibitors.
Monday, April 16, 2012
Proteros Appoints Dr Klaus Hinterding
Dr Klaus Hinterding, formerly at Hoffmann-La Roche Ltd, joins Proteros biostructures GmbH as Chief Scientific Officer and member of the management board.
Monday, February 13, 2012
Proteros Obtains CIR Accreditation
Accreditation allows eligible clients to receive 30% of their R&D costs in tax credits.
Wednesday, January 25, 2012
Rigel and Proteros Renew X-ray Protein Crystallography Collaboration
Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts.
Thursday, August 04, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos